Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» iptacopan
iptacopan
Novartis unveils promising Fabhalta data for C3 glomerulopathy indication
Medical Marketing and Media
Tue, 12/12/23 - 09:56 am
Novartis
clinical trials
Fabhalta
iptacopan
C3 glomerulopathy
Novartis receives FDA approval for Fabhalta to treat PNH in adults
Pharmaceutical Business Review
Wed, 12/6/23 - 10:25 am
Novartis
FDA
Fabhalta
iptacopan
PNH
paroxysmal nocturnal hemoglobinuria
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Clinical Trials Arena
Mon, 10/2/23 - 10:14 am
Novartis
clinical trials
iptacopan
IgA nephropathy
kidney disease
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
EHA 2023 – Astrazeneca keeps up its complement defense
EP Vantage
Fri, 06/9/23 - 10:01 am
EHA
AstraZeneca
Alexion
Soliris
Ultomiris
Novartis
iptacopan
PNH
Novartis’s iptacopan meets primary endpoint in Phase III PNH trial
Clinical Trials Arena
Thu, 04/27/23 - 10:30 am
Novartis
clinical trials
PNH
iptacopan
Could This Be Novartis' Next Blockbuster Medicine?
Motley Fool
Fri, 01/27/23 - 10:27 am
Novartis
iptacopan
PNH
ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca
Fierce Biotech
Tue, 12/13/22 - 10:28 am
ASH 2022
Novartis
iptacopan
AstraZeneca
Novartis' iptacopan meets PhIII test in fight against rare blood disease
Endpoints
Thu, 12/8/22 - 10:37 am
Novartis
clinical trials
paroxysmal nocturnal hemoglobinuria
iptacopan
Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3
Fierce Biotech
Mon, 10/24/22 - 11:17 pm
Novartis
iptacopan
clinical trials
Soliris
AstraZeneca
Ultomiris
Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial
Pharmaphorum
Mon, 10/24/22 - 10:47 am
Novartis
iptacopan
clinical trials
PNH
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Pharmaforum
Fri, 11/5/21 - 09:54 am
Novartis
iptacopan
C3G
kidney disease
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
Pharmaforum
Sat, 06/12/21 - 10:26 pm
Novartis
iptacopan
clinical trials
PNH
EHA
Novartis' Most Advanced Kidney Compound Shows Promise in C3G
BioSpace
Mon, 10/26/20 - 11:11 am
Novartis
ASN
C3G
clinical trials
iptacopan